These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37526844)

  • 1. Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products.
    Wang J; Griffiths E; Tounekti O; Nemec M; Deneault E; Lavoie JR; Ridgway A
    Adv Exp Med Biol; 2023; 1430():91-116. PubMed ID: 37526844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
    Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
    Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regulation of cell therapy products in Canada.
    Ridgway AA
    Biologicals; 2015 Sep; 43(5):406-9. PubMed ID: 26141550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada.
    Chisholm J; von Tigerstrom B; Bedford P; Fradette J; Viswanathan S
    Cytotherapy; 2017 Dec; 19(12):1400-1411. PubMed ID: 28964743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon.
    Chisholm J; Ruff C; Viswanathan S
    Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical device regulation for manufacturers.
    McAllister P; Jeswiet J
    Proc Inst Mech Eng H; 2003; 217(6):459-67. PubMed ID: 14702983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Oversight of Cell and Gene Therapy Products in Malaysia.
    Loh EYX; Ab Ghani A; Ahmad R
    Adv Exp Med Biol; 2023; 1430():181-195. PubMed ID: 37526848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Clinical Research for Cellular and Gene Therapy Products in India.
    Dalal V; Lata H; Kharkwal G; Jotwani G
    Adv Exp Med Biol; 2023; 1430():135-154. PubMed ID: 37526846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada.
    Bubela T; Boch R; Viswanathan S
    Front Med (Lausanne); 2019; 6():58. PubMed ID: 30984761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Oversight of Cell, Tissue, and Gene Therapy Products in Singapore.
    Ong LL
    Adv Exp Med Biol; 2023; 1430():197-210. PubMed ID: 37526849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Regulation of Cell Therapy and Gene Therapy Products in Switzerland.
    Bukovac PK; Hauser M; Lottaz D; Marti A; Schmitt I; Schochat T
    Adv Exp Med Biol; 2023; 1430():41-58. PubMed ID: 37526841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and challenges in viral vector manufacturing.
    van der Loo JC; Wright JF
    Hum Mol Genet; 2016 Apr; 25(R1):R42-52. PubMed ID: 26519140
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.